| 1 BCR-ABL as M Deininger Chronic Myeloid Leukemia, 1, 2006 | | 2006 |
| 143 EVALUATING THE CLINICAL UTILITY OF PERIPHERAL BLOOD SAMPLES FOR MOLECULAR EVALUATION OF MDS BY SNP-A EF Andersen, ME Salama, MC Sederberg, RM Toydemir, TJ Kovacsovics, ... Leukemia Research, S72, 2015 | | 2015 |
| 257: Validation of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after matched unrelated donor SCT T Kovacsovics, B Hayes-Lattin, K Riegert, N Subbiah, PT Curtin, JF Leis, ... Biology of Blood and Marrow Transplantation 13 (2), 94, 2007 | 2 | 2007 |
| 318: Busulfan, Fludarabine and Total Body Irradiation Followed by Allogeneic Peripheral Blood Stem Cell Transplantation is an Effective Treatment for Hematologic Malignancies … G Meyers, A Dunn, T Kovacsovics, W Fleming, E Epner, B Hayes-Lattin, ... Biology of Blood and Marrow Transplantation 14 (2), 117, 2008 | 1 | 2008 |
| 4-Year results from the pivotal phase 2 PACE trial: efficacy and safety in heavily pretreated leukemia patients J Cortes, J Pinilla-Ibarz, P le Coutre, R Paquette, C Chuah, F Nicolini, ... Clinical Lymphoma, Myeloma and Leukemia 16, S56, 2016 | 2 | 2016 |
| 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia. JE Cortes, J Pinilla-Ibarz, PD Le Coutre, R Paquette, C Chuah, FE Nicolini, ... Journal of Clinical Oncology 34 (15_suppl), 7013-7013, 2016 | 8 | 2016 |
| 467: Clonazepam Plus Levetiracetam (CL) for the Prevention of Busulfan-Induced Seizures: A Single Center Experience JS Bubalo, TJ Kovascovics, G Meyers, M Mauro, E Epner, B Hayes-Lattin, ... Biology of Blood and Marrow Transplantation 14 (2), 165, 2008 | 4 | 2008 |
| 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia JE Cortes, HM Kantarjian, J Pinilla-Ibarz, PD le Coutre, R Paquette, ... Clinical Lymphoma, Myeloma and Leukemia 17, S307-S308, 2017 | 2 | 2017 |
| 5-yr results from the pivotal phase 2 ponatinib pace trial: Efficacy, safety and landmark analysis in heavily pretreated patients (pts) with chronic-phase chronic myeloid … JE Cortes, HM Kantarjian, J Pinilla-Ibarz, PD le Coutre, R Paquette, ... HAEMATOLOGICA 102, 236-237, 2017 | 1 | 2017 |
| A 14q32. 31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity G Silvestri, R Trotta, L Stramucci, S Wang, AK Eisfeld, B Zhang, K Srutova, ... Blood 134, 4141, 2019 | 1 | 2019 |
| A 3-part, phase 2 study of Bezuclastinib (CGT9486), an oral, selective, and potent KIT D816V inhibitor, in adult patients with nonadvanced systemic mastocytosis (NonAdvSM) F Siebenhaar, J Gotlib, MW Deininger, DJ DeAngelo, F Payumo, ... Blood 138, 3642, 2021 | 3 | 2021 |
| A Bayesian framework to study tumor subclone–specific expression by combining bulk DNA and single-cell RNA sequencing data Y Qiao, X Huang, PJ Moos, JM Ahmann, AD Pomicter, MW Deininger, ... Genome research 34 (1), 94-105, 2024 | 1 | 2024 |
| A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice KJ Johnson, IJ Griswold, T O'Hare, AS Corbin, M Loriaux, MW Deininger, ... PloS one 4 (10), e7439, 2009 | 35 | 2009 |
| A Bcr-Abl Mutant Lacking Direct Binding Sites for the Grb2, Cbl and CrkL Adapter Proteins Fails to Induce Leukemia in Mice. KJ Johnson, IJ Griswold, A Corbin, MWN Deininger, BJ Druker Blood, The Journal of the American Society of Hematology 104 (11), 718-718, 2004 | | 2004 |
| A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia DW Woessner, AM Eiring, BJ Bruno, MS Zabriskie, KR Reynolds, ... Leukemia 29 (8), 1668-1675, 2015 | 16 | 2015 |
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis S Verstovsek, RA Mesa, J Gotlib, RS Levy, V Gupta, JF DiPersio, ... New England Journal of Medicine 366 (9), 799-807, 2012 | 2252 | 2012 |
| A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib SK McWeeney, LC Pemberton, MM Loriaux, K Vartanian, SG Willis, ... Blood, The Journal of the American Society of Hematology 115 (2), 315-325, 2010 | 137 | 2010 |
| A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors. LC Crossman, T O’Hare, T Lange, SG Willis, EP Stoffregen, AS Corbin, ... Blood, The Journal of the American Society of Hematology 106 (11), 1530-1530, 2005 | | 2005 |
| A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response RD Press, C Galderisi, R Yang, C Rempfer, SG Willis, MJ Mauro, ... Clinical Cancer Research 13 (20), 6136-6143, 2007 | 152 | 2007 |
| A half-log increase in quantitative RT-PCR for BCR-ABL (RQ-PCR) as a trigger for kinase domain mutation analysis. RD Press, S Willis, C Rempfer, MJ Mauro, BJ Druker, MWN Deininger Blood, The Journal of the American Society of Hematology 108 (11), 2152-2152, 2006 | | 2006 |
